Organon & Co. Cost of Revenue
Organon & Co. (OGN) reported Cost of Revenue of $711.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-31
- Organon & Co. cost of goods and services sold for the quarter ending 2026-06-30 was $711.00M, a 1.25% decline year-over-year.
- Organon & Co. cost of goods and services sold for the quarter ending 2026-03-31 was $677.00M, a 0.74% increase year-over-year.
- Organon & Co. cost of goods and services sold for the quarter ending 2025-12-31 was $766.00M, a 10.06% increase year-over-year.
- Organon & Co. cost of goods and services sold for the quarter ending 2025-09-30 was $745.00M, a 13.05% increase year-over-year.
- Organon & Co. cost of goods and services sold for fiscal 2025 was $2.90B, a 8.00% increase from fiscal 2024.
- Organon & Co. cost of goods and services sold for fiscal 2024 was $2.69B, a 6.88% increase from fiscal 2023.
- Organon & Co. cost of goods and services sold for fiscal 2023 was $2.52B, a 9.63% increase from fiscal 2022.
- Organon & Co. cost of goods and services sold for fiscal 2022 was $2.29B, a 3.69% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $711.00M 10-Q · filed 2026-07-31 | $1.39B 10-Q · filed 2026-07-31 | $2.15B derived: sum of 3 quarters · filed 2026-07-31 | $2.90B derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $677.00M 10-Q · filed 2026-05-04 | $1.44B derived: sum of 2 quarters · filed 2026-05-04 | $2.19B derived: sum of 3 quarters · filed 2026-05-04 | $2.91B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $766.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.51B derived: sum of 2 quarters · filed 2026-02-24 | $2.23B derived: sum of 3 quarters · filed 2026-07-31 | $2.90B 10-K · filed 2026-02-24 |
| 2025-09-30 | $745.00M 10-Q · filed 2025-11-10 | $1.47B derived: sum of 2 quarters · filed 2026-07-31 | $2.14B 10-Q · filed 2025-11-10 | $2.83B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $720.00M 10-Q · filed 2026-07-31 | $1.39B 10-Q · filed 2026-07-31 | $2.09B derived: sum of 3 quarters · filed 2026-07-31 | $2.75B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $672.00M 10-Q · filed 2026-05-04 | $1.37B derived: sum of 2 quarters · filed 2026-05-04 | $2.03B derived: sum of 3 quarters · filed 2026-05-04 | $2.69B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $696.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.35B derived: sum of 2 quarters · filed 2026-02-24 | $2.02B derived: sum of 3 quarters · filed 2026-02-24 | $2.69B 10-K · filed 2026-02-24 |
| 2024-09-30 | $659.00M 10-Q · filed 2025-11-10 | $1.33B derived: sum of 2 quarters · filed 2025-11-10 | $1.99B 10-Q · filed 2025-11-10 | $2.67B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $668.00M 10-Q · filed 2025-08-06 | $1.33B 10-Q · filed 2025-08-06 | $2.02B derived: sum of 3 quarters · filed 2026-02-24 | $2.63B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $665.00M 10-Q · filed 2025-05-02 | $1.35B derived: sum of 2 quarters · filed 2026-02-24 | $1.96B derived: sum of 3 quarters · filed 2026-02-24 | $2.60B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $683.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.29B derived: sum of 2 quarters · filed 2026-02-24 | $1.94B derived: sum of 3 quarters · filed 2026-02-24 | $2.52B 10-K · filed 2026-02-24 |
| 2023-09-30 | $612.00M 10-Q · filed 2024-11-01 | $1.25B derived: sum of 2 quarters · filed 2024-11-01 | $1.83B 10-Q · filed 2024-11-01 | $2.43B derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $640.00M 10-Q · filed 2024-08-07 | $1.22B 10-Q · filed 2024-08-07 | $1.81B derived: sum of 3 quarters · filed 2025-11-10 | $2.37B derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $580.00M 10-Q · filed 2024-05-03 | $1.17B derived: sum of 2 quarters · filed 2025-11-10 | $1.73B derived: sum of 3 quarters · filed 2025-11-10 | $2.31B derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $594.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $1.15B derived: sum of 2 quarters · filed 2025-11-10 | $1.73B derived: sum of 3 quarters · filed 2025-11-10 | $2.29B 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $551.00M 10-Q · filed 2023-11-03 | $1.14B derived: sum of 2 quarters · filed 2023-11-03 | $1.70B 10-Q · filed 2023-11-03 | $2.30B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $588.00M 10-Q · filed 2023-08-09 | $1.15B 10-Q · filed 2023-08-09 | $1.75B derived: sum of 3 quarters · filed 2024-02-26 | $2.36B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $561.00M 10-Q · filed 2023-05-05 | $1.16B derived: sum of 2 quarters · filed 2024-02-26 | $1.77B derived: sum of 3 quarters · filed 2024-02-26 | $2.35B derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $599.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.21B derived: sum of 2 quarters · filed 2024-02-26 | $1.79B derived: sum of 3 quarters · filed 2024-02-26 | $2.38B 10-K · filed 2024-02-26 |
| 2021-09-30 | $609.00M 10-Q · filed 2022-11-04 | $1.19B derived: sum of 2 quarters · filed 2022-11-04 | $1.78B 10-Q · filed 2022-11-04 | $2.37B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $583.00M 10-Q · filed 2022-08-05 | $1.17B 10-Q · filed 2022-08-05 | $1.76B derived: sum of 3 quarters · filed 2023-02-27 | $2.29B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $591.00M 10-Q · filed 2022-05-06 | $1.18B derived: sum of 2 quarters · filed 2023-02-27 | $1.71B derived: sum of 3 quarters · filed 2023-02-27 | $2.17B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $586.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.12B derived: sum of 2 quarters · filed 2023-02-27 | $1.58B derived: sum of 3 quarters · filed 2023-02-27 | $2.12B 10-K · filed 2023-02-27 |
| 2020-09-30 | $535.00M 10-Q · filed 2021-11-12 | $995.00M derived: sum of 2 quarters · filed 2021-11-12 | $1.53B 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $460.00M 10-Q · filed 2021-08-16 | $998.00M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $538.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $2.27B 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |